Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,511.00-0.52%ETH$2,696.35-0.71%GOLD$4,192.90+0.14%OIL$89.86+0.47%
Smart Investors Daily
SID Premium
IN

NASDAQ · INBX

Inhibrx Biosciences, Inc.

Healthcare · Biotechnology

$94.56

Down-$1.15 (-1.22%)

Updated Oct 6, 2026, 11:00 PM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.2B
P/E ratio
-8.2
Dividend yield
0.00%
52-week range
$57.30 – $155.29
Volume
207.09K
Avg. volume
370.47K

Price performance · INBX

INBX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

INBX closed at $94.56 after 20 trading sessions, down 17.30% for the selected period.

Last close
$94.56
Period change
-17.30%
Period low
$94.56
Period high
$114.34
Daily close
View OHLC price history
INBX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$97.56$98.5054$94.18$94.56207.09K
Oct 2, 2026$99.30$100.125$96.07$96.99201.45K
Oct 1, 2026$100.71$102.16$97.5758$97.93216.61K
Sep 30, 2026$105.67$106.94$100.08$100.08389.48K
Sep 29, 2026$105.31$107.90$102.51$104.83240.94K
Sep 28, 2026$98.69$104.55$98.51$101.71188.88K
Sep 25, 2026$101.29$101.29$98.09$99.61158.66K
Sep 24, 2026$102.38$104.49$99.53$100.40285.79K
Sep 23, 2026$110.12$110.88$98.56$100.33375.3K
Sep 22, 2026$112.45$117.14$109.05$110.67292.15K
Sep 21, 2026$112.69$113.185$108.945$112.04249.13K
Sep 18, 2026$106.45$110.41$105.04$109.35483.38K
Sep 17, 2026$103.73$108.00$103.73$104.73217.28K
Sep 16, 2026$105.61$106.44$99.055$101.77363.49K
Sep 15, 2026$109.44$109.44$104.845$105.61251.6K
Sep 14, 2026$109.10$111.44$104.90$110.47239.99K
Sep 11, 2026$113.00$115.11$108.93$109.27211.02K
Sep 10, 2026$109.23$113.949$107.22$111.42313.89K
Sep 9, 2026$117.38$128.54$112.03$112.86677.83K
Sep 8, 2026$117.22$120.1825$94.0001$114.341.68M

Latest INBX news

The latest Smart Investors Daily articles mentioning INBX.

Stock researchCompany · Overview

INBX research

Overview

Company profile and research snapshot.

Company profile

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$12.24
Implied upside
—
Analysts
6
INBX recent ratings
DateFirmRatingTarget
Aug 24, 2026HC Wainwright & Co.Buy—
Apr 8, 2026StifelBuy—
Aug 22, 2025JMP SecuritiesMarket Perform—
May 15, 2025JMP SecuritiesMarket Perform—
Mar 18, 2025Citizens Capital MarketsMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating

Inhibrx Biosciences (INBX) has drawn investor attention after a sharp move in the share price. The US$101.71 close now sits alongside a year-to-date gain of about 35%. Recent trading has been choppy, with a 1-day share price return of 2.11% following a 7-day share price return that fell 9.22% and a 30-day share price return down 17.58%. Despite this, Inhibrx Biosciences still shows a year-to-date share price return of 35.54% and a very large 1-year total shareholder return of 214.79%. This...

Yahoo · Sep 24, 2026

Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?

Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors’ attention. Its experimental cancer drug INBRX-106, combined with Merck’s Keytruda, produced a confirmed response rate nearly twice that of Keytruda alone in a Phase 2 head and neck cancer study. The results were even stronger among a […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By